Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 3Urogenital Neoplasms 1Prostatic Neoplasms, Castration-Resistant 1Prostatic Diseases 1Neoplasms by Site 1Neoplasms 1Genital Neoplasms, Male 1Genital Diseases, Male 1Disease 1

Interventions

pembrolizumab 3fludarabine 3aldesleukin 3Cyclophosphamide 3cabozantinib 2Specimen Handling 2Nivolumab 2Magnetic Resonance Spectroscopy 2Ipilimumab 2Fecal Microbiota Transplantation 2CTLA-4 Antigen 2vedolizumab 1prednylidene 1olaparib 1gallium 68 PSMA-11 1enfortumab vedotin 1deltacortene 1darolutamide 1Therapeutics 1Standard of Care 1Radiosurgery 1Radiation Dose Hypofractionation 1Prednisone 1Practice Guidelines as Topic 1Pluvicto 1Mitomycin 1Lutetium-177 1Lutetium 1Loperamide 1LDP-02 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Urogenital Neoplasms × (225)Ac-PSMA-617 × 90 days × Clear all
NCT04597411 2026-04-30

Study of 225Ac-PSMA-617 in Men With PSMA-positive Prostate Cancer

Endocyte

Phase 1 Active not recruiting
101 enrolled
Genitourinary

Genital Diseases, Male, Genital Neoplasms, Male, Neoplasms, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms, Prostatic Neoplasms, Castration-Resistant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡